Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

CompletedOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Gastric Cancer
Trial Locations (31)

112

Taipei Veterans General Hospital, Taipei

704

National Cheng Kung University Hospital, Tainan City

28644

Chungbuk National University Hospital, Cheongju-si

33305

Linkou Chang Gung Memorial Hospital, Taoyuan District

61363

Chiayi Chang Gung Memorial Hospital, Chiayi City

200433

Shanghai Changhai Hospital, Shanghai

230022

The First Affiliated Hospital of Anhui Medical University, Hefei

300060

Tianjin Medical University Hospital, Tianjin

310017

Second Affiliated Hospital ZheJiang University School of Medicine, Zhejiang

430079

Hubei Cancer Hospital, Hubei

450003

Henan Cancer Hospital, Zhengzhou

510060

Sun Yat-sen University Cancer Center, Guangdong

610041

Sichuan Cancer Hospital, Chengdu

Unknown

Queen Mary Hospital, Pok Fu Lam

Prince of Wales Hospital, Shatin

Tuen Mun Hospital, Tuenmen

Dong-A University Hospital, Busan

Kyungpook National University Chillgok Hospital, Deagu

Pusan National University Yangsan Hospital, Gyeongsangnam-do

Korea University Anam Hospital, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

Kaohsiung Medical University Hospital, Kaohsiung City

China Medical University Hospital, Taichung

Chi Mei Medical Center, Tainan City

Koo Foundation Sun Yat-Sen Cancer Center, Taipei

MacKay Memorial Hospital, Taipei

04514

Kangbuk Samsung Hospital, Seoul

06351

Samsung Medical Center, Seoul

06973

Chung-Ang University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT05606094 - Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia | Biotech Hunter | Biotech Hunter